84 related articles for article (PubMed ID: 19744185)
1. CDKs as therapeutic targets for the human genetic disease tuberous sclerosis?
Rosner M; Dolznig H; Fuchs C; Siegel N; Valli A; Hengstschläger M
Eur J Clin Invest; 2009 Dec; 39(12):1033-5. PubMed ID: 19744185
[TBL] [Abstract][Full Text] [Related]
2. p27Kip1 localization depends on the tumor suppressor protein tuberin.
Rosner M; Freilinger A; Hanneder M; Fujita N; Lubec G; Tsuruo T; Hengstschläger M
Hum Mol Genet; 2007 Jul; 16(13):1541-56. PubMed ID: 17470459
[TBL] [Abstract][Full Text] [Related]
3. Cytoplasmic/nuclear localization of tuberin in different cell lines.
Rosner M; Hengstschläger M
Amino Acids; 2007 Nov; 33(4):575-9. PubMed ID: 17458623
[TBL] [Abstract][Full Text] [Related]
4. Akt regulates nuclear/cytoplasmic localization of tuberin.
Rosner M; Freilinger A; Hengstschläger M
Oncogene; 2007 Jan; 26(4):521-31. PubMed ID: 16862180
[TBL] [Abstract][Full Text] [Related]
5. A growth factor-dependent nuclear kinase phosphorylates p27(Kip1) and regulates cell cycle progression.
Boehm M; Yoshimoto T; Crook MF; Nallamshetty S; True A; Nabel GJ; Nabel EG
EMBO J; 2002 Jul; 21(13):3390-401. PubMed ID: 12093740
[TBL] [Abstract][Full Text] [Related]
6. The tuberous sclerosis genes and regulation of the cyclin-dependent kinase inhibitor p27.
Rosner M; Freilinger A; Hengstschläger M
Mutat Res; 2006 Sep; 613(1):10-6. PubMed ID: 16713332
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.
Lee L; Sudentas P; Donohue B; Asrican K; Worku A; Walker V; Sun Y; Schmidt K; Albert MS; El-Hashemite N; Lader AS; Onda H; Zhang H; Kwiatkowski DJ; Dabora SL
Genes Chromosomes Cancer; 2005 Mar; 42(3):213-27. PubMed ID: 15578690
[TBL] [Abstract][Full Text] [Related]
8. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.
Kenerson HL; Aicher LD; True LD; Yeung RS
Cancer Res; 2002 Oct; 62(20):5645-50. PubMed ID: 12384518
[TBL] [Abstract][Full Text] [Related]
9. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment.
Jozwiak J; Jozwiak S; Oldak M
Med Res Rev; 2006 Mar; 26(2):160-80. PubMed ID: 16329102
[TBL] [Abstract][Full Text] [Related]
10. Tuberin, p27 and mTOR in different cells.
Burgstaller S; Rosner M; Lindengrün C; Hanneder M; Siegel N; Valli A; Fuchs C; Hengstschläger M
Amino Acids; 2009 Feb; 36(2):297-302. PubMed ID: 18386114
[TBL] [Abstract][Full Text] [Related]
11. Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase.
Calastretti A; Bevilacqua A; Ceriani C; Viganò S; Zancai P; Capaccioli S; Nicolin A
Oncogene; 2001 Sep; 20(43):6172-80. PubMed ID: 11593425
[TBL] [Abstract][Full Text] [Related]
12. The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners.
Rosner M; Hanneder M; Siegel N; Valli A; Hengstschläger M
Mutat Res; 2008; 658(3):234-46. PubMed ID: 18291711
[TBL] [Abstract][Full Text] [Related]
13. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
14. cAMP-dependent cytosolic mislocalization of p27(kip)-cyclin D1 during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.
Cohen JD; Tham KY; Mastrandrea NJ; Gallegos AC; Monks TJ; Lau SS
Toxicol Sci; 2011 Aug; 122(2):361-71. PubMed ID: 21693435
[TBL] [Abstract][Full Text] [Related]
15. Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization.
Bhatia B; Northcott PA; Hambardzumyan D; Govindarajan B; Brat DJ; Arbiser JL; Holland EC; Taylor MD; Kenney AM
Cancer Res; 2009 Sep; 69(18):7224-34. PubMed ID: 19738049
[TBL] [Abstract][Full Text] [Related]
16. The pathophysiology of tuberous sclerosis complex.
Crino PB
Epilepsia; 2010 Feb; 51 Suppl 1():27-9. PubMed ID: 20331708
[No Abstract] [Full Text] [Related]
17. The function of p27 KIP1 during tumor development.
Lee J; Kim SS
Exp Mol Med; 2009 Nov; 41(11):765-71. PubMed ID: 19887899
[TBL] [Abstract][Full Text] [Related]
18. Emerging treatments in the management of tuberous sclerosis complex.
Kohrman MH
Pediatr Neurol; 2012 May; 46(5):267-75. PubMed ID: 22520346
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis.
Paul E; Thiele E
N Engl J Med; 2008 Jan; 358(2):190-2. PubMed ID: 18184966
[No Abstract] [Full Text] [Related]
20. AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27.
Short JD; Houston KD; Dere R; Cai SL; Kim J; Johnson CL; Broaddus RR; Shen J; Miyamoto S; Tamanoi F; Kwiatkowski D; Mills GB; Walker CL
Cancer Res; 2008 Aug; 68(16):6496-506. PubMed ID: 18701472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
